Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).

Eur Heart J · 2020 · PMC7550197 · PMID 32820334

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

The proportion of participants reporting a ≥ 5-point improvement in KCCQ-TSS varied inconsistently across SBP categories, with an interaction between baseline SBP and treatment with dapagliflozin of borderline significance ( P -value for interaction = 0.04).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.